Lumida
/AUPH
⌘K
Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

AUPH
$15.96USD+0.13%+0.02 today

MARKET CAP

2.1B

P/E (TTM)

17.7x

FWD P/E

16.1x

DAY RANGE

$16 – $16

52W RANGE

$9
$19

AI Summary

Stalk
TrimMedium

The stock is in a Stage 4 decline with bearish pivot structure and lower highs/lows. The medium-term bias is bearish with no mean-reversion eligibility. Short-term price is trading below declining 9/21 EMAs without exhaustion, making rallies into this EMA zone the optimal sell execution area. Execution is deferred until price approaches the short-EMA resistance for higher-probability entry.

  • Q4 2025 revenue of $77.1M, up 29% YoY
  • 2026 net product sales expected $305M–$315M (+12%–16%)
  • Exclusivity ends January 2026; generic entrants threaten market share
Full analysis →